<DOC>
	<DOCNO>NCT02953496</DOCNO>
	<brief_summary>The research study design assess technical feasibility safety percutaneous administration vonapanitase superficial femoral popliteal artery patient PAD .</brief_summary>
	<brief_title>Safety/Feasibility Percutaneous Administration Vonapanitase Monotherapy Peripheral Artery Disease ( PAD ) SFA Popliteal Arteries</brief_title>
	<detailed_description />
	<mesh_term>Peripheral Arterial Disease</mesh_term>
	<criteria>1 . Age least 18 year . 2 . Clinical diagnosis PAD secondary atherosclerosis affect low limb . 3 . ABI &lt; 0.90 rest exercise , toebrachial index ( TBI ) &lt; 0.70 ABI value &gt; 1.30 ( noncompressible ) , radiographic evidence PAD correlate clinical symptom . 4 . Rutherford category 24 . 5 . Screening duplex Doppler ultrasound SFA PA lesion PSVR &gt; 2.4 . 6 . De novo lesion , previously treat angioplasty , atherectomy , stent . 7 . If female childbearing potential ( premenopausal surgically sterile ) must negative pregnancy test screen visit willing use contraception time screen visit 1 week follow study drug administration . Acceptable method birth control include abstinence , barrier method spermicide , implant , injectables , oral contraceptive , intrauterine device , vasectomized partner . 8 . Ability understand comply requirement entire study communicate study team . 9 . Ability provide write informed consent use document approve required institutional review board . Exclusion Criteria 1 . Patients arterial insufficiency lower extremity result immunologic inflammatory nonatherosclerotic disorder ( e.g. , Buerger 's disease , vasculitis ) . 2 . Total occlusion SFA PA index leg . 3 . Planned surgical endovascular procedure affect leg day within 28 day study drug administration . 4 . Deep vein thrombosis within past 3 month . 5 . Known bleed disorder . 6 . Presence arterial aneurysm index leg . 7 . Known hypercoagulable state ( e.g. , protein C deficiency , factor V Leiden mutation , prothrombin G20210A mutation ) . 8 . Platelet count &lt; 130K , hematocrit &lt; 30 % , bilirubin ALT &gt; 3.0 time upper limit normal . 9 . Arterial systolic BP &gt; 200 mmHg diastolic BP &gt; 100 mmHg screen day procedure . 10 . Pregnancy , lactation plan become pregnant course study . 11 . Presence significant medical condition might significantly confound collection safety efficacy data study . 12 . Malignancy treatment malignancy within previous 12 month exception localize basal cell squamous cell skin cancer , cancer situ . 13 . Treatment investigational drug within previous 30 day investigational antibody therapy within 90 day prior sign inform consent . 14 . Known allergy contrast medium , iodine , lidocaine , prilocaine , EMLA Cream ( lidocaine 2.5 % prilocaine 2.5 % ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>100 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>peripheral artery disease</keyword>
	<keyword>PAD</keyword>
	<keyword>vonapanitase</keyword>
	<keyword>claudication</keyword>
	<keyword>superficial femoral artery</keyword>
	<keyword>SFA</keyword>
	<keyword>popliteal artery</keyword>
	<keyword>stenosis</keyword>
	<keyword>elastase</keyword>
	<keyword>chymotrypsin-like elastase 1</keyword>
	<keyword>CELA1</keyword>
	<keyword>PRT-201</keyword>
</DOC>